Study identifier:NIS-NKR-SER-2007/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 8-week, Multicenter, Open-label, Observational study of the efficacy of Quetiapine Fumarate (SEROQUEL) Immediate-release tablets in adult patients with bipolar depression
bipolar depression
-
No
-
All
2000
Observational
18 Years - 65 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
To reassure the clinical study data on Seroquel antidepressant efficacy in patients who are diagnosed as bipolar depression
Location
Location
Kyungki-do, Goyang-si, Republic of Korea
Location
Daejun, Kwangyuk-si, Republic of Korea
Location
Kyungki-do, Suwon-si, Republic of Korea
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.